Camarda Financial Advisors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $380K | Sell |
317
-90
| -22% | -$92K | 0.12% | 98 |
|
|
2026
Q1 | $374K | Sell |
407
-3,018
| -88% | -$3.06M | 0.2% | 88 |
|
|
2025
Q4 | $3.68M | Buy |
+3,425
| New | +$3.27M | 1.4% | 16 |
|
|
2025
Q2 | – | Sell |
-249
| Closed | -$206K | – | 111 |
|
|
2025
Q1 | $206K | Sell |
249
-30
| -11% | -$25K | 0.09% | 94 |
|
|
2024
Q4 | $215K | Sell |
279
-60
| -18% | -$49.7K | 0.08% | 93 |
|
|
2024
Q3 | $300K | Buy |
339
+4
| +1% | +$3.6K | 0.11% | 76 |
|
|
2024
Q2 | $303K | Buy |
335
+3
| +0.9% | +$2.4K | 0.12% | 71 |
|
|
2024
Q1 | $258K | Sell |
332
-267
| -45% | -$190K | 0.1% | 68 |
|
|
2023
Q4 | $349K | Hold |
599
| – | – | 0.15% | 71 |
|
|
2023
Q3 | $322K | Hold |
599
| – | – | 0.21% | 60 |
|
|
2023
Q2 | $281K | Sell |
599
-25
| -4% | -$10.5K | 0.14% | 65 |
|
|
2023
Q1 | $214K | Hold |
624
| – | – | 0.16% | 59 |
|
|
2022
Q4 | $228K | Hold |
624
| – | – | 0.23% | 72 |
|
|
2022
Q3 | $202K | Hold |
624
| – | – | 0.24% | 64 |
|
|
2022
Q2 | $202K | Buy |
+624
| New | +$187K | 0.2% | 70 |
|
|
2021
Q4 | – | Sell |
-3,602
| Closed | -$832K | – | 106 |
|
|
2021
Q3 | $832K | Buy |
+3,602
| New | +$889K | 0.56% | 27 |
|
|
2019
Q3 | – | Sell |
-348
| Closed | -$39K | – | 289 |
|
|
2019
Q2 | $39K | Sell |
348
-41
| -11% | -$4.83K | 0.08% | 85 |
|
|
2019
Q1 | $51K | Sell |
389
-108
| -22% | -$13.1K | 0.1% | 79 |
|
|
2018
Q4 | $58K | Hold |
497
| – | – | 0.07% | 75 |
|
|
2018
Q3 | $53K | Hold |
497
| – | – | 0.06% | 108 |
|
|
2018
Q2 | $42K | Hold |
497
| – | – | 0.04% | 114 |
|
|
2018
Q1 | $38K | Buy |
+497
| New | +$40K | 0.04% | 111 |
|
|
2017
Q1 | – | Sell |
-44
| Closed | -$3K | – | 219 |
|
|
2016
Q4 | $3K | Buy |
+44
| New | +$3.28K | ﹤0.01% | 207 |
|
|
2015
Q2 | – | Sell |
-4,982
| Closed | -$362K | – | 252 |
|
|
2015
Q1 | $362K | Buy |
4,982
+262
| +6% | +$18.7K | 0.2% | 70 |
|
|
2014
Q4 | $326K | Buy |
4,720
+877
| +23% | +$59.2K | 0.21% | 74 |
|
|
2014
Q3 | $249K | Sell |
3,843
-1,598
| -29% | -$101K | 0.17% | 74 |
|
|
2014
Q2 | $338K | Buy |
5,441
+3,557
| +189% | +$212K | 0.23% | 75 |
|
|
2014
Q1 | $111K | Sell |
1,884
-249
| -12% | -$13.9K | 0.09% | 87 |
|
|
2013
Q4 | $109K | Sell |
2,133
-339
| -14% | -$17K | 0.09% | 75 |
|
|
2013
Q3 | $124K | Buy |
2,472
+896
| +57% | +$46.9K | 0.16% | 56 |
|
|
2013
Q2 | $77K | Buy |
+1,576
| New | +$85.8K | 0.07% | 99 |
|
Other funds holding LLY
Camarda Financial Advisors's LLY Position: Q2 2026 in Review
Camarda Financial Advisors reduced its Eli Lilly (LLY) stake by 22% in Q2 2026, selling an estimated $92K and leaving 317 shares worth $380K. The position accounts for 0.12% of the portfolio, ranked #98.
Camarda Financial Advisors first reported a position in LLY in Q2 2013 and has held it in 31 quarters since. The position peaked at $3.68M in Q4 2025. 4,599 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Camarda Financial Advisors held 317 shares of Eli Lilly worth $380K as of Q2 2026.
- Camarda Financial Advisors sold 90 Eli Lilly shares in Q2 2026, an estimated $92K.
- Eli Lilly made up 0.12% of Camarda Financial Advisors's portfolio in Q2 2026, its #98 holding.
- Camarda Financial Advisors first reported a position in Eli Lilly in Q2 2013 and has held it in 31 quarters since.
- Camarda Financial Advisors's Eli Lilly position peaked at $3.68M in Q4 2025.
- 4,599 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Camarda Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.